Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Italy's therapeutic AIDS vaccine shows drastic reduction of HIV virus reservoirs: study

Clinical trials of an Italian therapeutic vaccine against AIDS showed a drastic reduction of virus reservoirs in treated patients, Italian researchers said on Wednesday.

Published
14 March 2019
From
Xinhua
TB CAB statement on safety of using bedaquiline and delamanid together

he Global TB Community Advisory Board (TB CAB) welcomes the important finding from the AIDS Clinical Trials Group Deliberate Trial that newer drugs bedaquiline and delamanid are safe to use together. These findings should erase any remaining reluctance to use these two important drugs together, as the benefits of these safer drugs outweigh the risks--especially for patients with drug-resistant TB who have few other treatment options.

Published
14 March 2019
From
TB Online
Large French study examines neuropsychiatric side effects with integrase inhibitors

The largest prospective study to date on integrase inhibitors and their potential for being associated with neuropsychiatric side effects was conducted in France. With more than 21,000 HIV-positive participants, the study found that the proportion of people who stopped taking integrase inhibitors due to neuropsychiatric side effects was generally very low (between 1% and 3%). Of particular note is the fact that before starting treatment with an integrase-inhibitor-containing regimen, between 3% and 10% of participants had previously reported neuropsychiatric side effects with other classes of HIV treatment.

Published
12 March 2019
From
CATIE
Can high-dose dolutegravir be a rescue therapy?

A small study in Italy found that high doses of the powerful integrase inhibitor dolutegravir (Tivicay, and also found in Juluca and Triumeq) can be used as a key part of rescue therapy for people with HIV that has extensive drug resistance to treatment. When doctors doubled the dose typically prescribed for treatment-experienced people to 100 mg twice daily, they found that high-dose dolutegravir was well absorbed with no occurrence of neuropsychiatric or serious side effects.

Published
12 March 2019
From
CATIE
CROI 2019: Will the “Düsseldorf patient” make three — further propelling cure research?

Five years after a stem cell transplant with the same critical factor as those received by the Berlin patient and the London patient, and four months after stopping antiretroviral treatment, a Düsseldorf man remains virally suppressed

Published
12 March 2019
From
Science Speaks
Wider ART Rollout Tied to Declines in HIV Mortality in Kenya

Both all-cause mortality and mortality among HIV-positive people dropped in Western Kenya following a scale-up of antiretroviral therapy (ART), a researcher said here. From 2011 to 2016, all-cause mortality dropped from 10.0 per 1,000 person years (95% CI 8.4-11.7) to 7.5 per 1,000 person years (95% CI 5.8-9.1), reported Emily C. Zielinski-Gutierrez, DrPH, of the CDC.

Published
12 March 2019
From
MedPage Today
Anthony Fauci: Physicians cured a man of HIV, but that's not our best shot at fighting AIDS

The Berlin and London patients give important insights for HIV researchers, and a cure for HIV is an aspiration we continue to pursue. But the end of the epidemic - the reduction of new HIV infections and HIV-related deaths to very low levels - is within our reach even without a cure.

Published
12 March 2019
From
Sydney Morning Herald
Laura Waters, MD, FRCP: Can Two Drugs Tango?

In a symposium presentation at the Annual Conference on Retroviruses and Opportunistic Infections (CROI 2019), Laura Waters, MD, FRCP, discussed the developments of 2-drug regimens for HIV treatments, as well as the questions that remain unanswered. Contagion® sat down with Dr. Waters for an exclusive interview about her presentation and to discuss new data from several studies presented at the meeting.

Published
12 March 2019
From
Contagion Live
Double doses of darunavir given with rifampicin lead to high rates of hepatoxicity

Adjusted doses of darunavir/ritonavir (DRV/r) with rifampicin (RIF) were associated with unacceptable risk of hepatotoxicity and a reduction in DRV trough concentrations in a pharmacokinetic (PK) study, conducted in South Africa, presented at CROI 2019.


Published
12 March 2019
From
HIV i-Base
What You Need to Know About the Second Person Likely Cured of HIV

Interview with Richard Jefferys, the Basic Science, Vaccines, and Cure Project Director of Treatment Action Group, about the significance of the second person seemingly cured of HIV, what both community members and journalists should know about this study, and how HIV cure research stories in the mainstream press can create false hope for people living with HIV.

Published
11 March 2019
From
The Body Pro

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.